These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20308443)

  • 1. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation.
    Chen JH; Nie K; Bahri S; Hsu CC; Hsu FT; Shih HN; Lin M; Nalcioglu O; Su MY
    Radiology; 2010 Apr; 255(1):44-52. PubMed ID: 20308443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
    Baek HM; Chen JH; Nie K; Yu HJ; Bahri S; Mehta RS; Nalcioglu O; Su MY
    Radiology; 2009 Jun; 251(3):653-62. PubMed ID: 19276320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR.
    Chen JH; Pan WF; Kao J; Lu J; Chen LK; Kuo CC; Chang CK; Chen WP; McLaren CE; Bahri S; Mehta RS; Su MY
    NMR Biomed; 2013 Dec; 26(12):1705-13. PubMed ID: 23940080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
    Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
    Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
    Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V
    Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
    Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
    Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parameters.
    O'Flynn EA; Collins D; D'Arcy J; Schmidt M; de Souza NM
    Eur J Radiol; 2016 Apr; 85(4):837-42. PubMed ID: 26971432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study.
    Zer A; Rizel S; Braunstein R; Yerushalmi R; Hendler D; Neimann V; Cioreuru N; Sulkes A; Stemmer SM
    Chemotherapy; 2012; 58(2):95-101. PubMed ID: 22377846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
    Gradishar WJ; Wedam SB; Jahanzeb M; Erban J; Limentani SA; Tsai KT; Olsen SR; Swain SM
    Ann Oncol; 2005 Aug; 16(8):1297-304. PubMed ID: 15905305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
    Park SH; Moon WK; Cho N; Song IC; Chang JM; Park IA; Han W; Noh DY
    Radiology; 2010 Oct; 257(1):56-63. PubMed ID: 20851939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
    Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.
    Martincich L; Montemurro F; Cirillo S; Marra V; De Rosa G; Ponzone R; Aglietta M; Regge D
    Radiol Med; 2003; 106(1-2):51-8. PubMed ID: 12951551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.